Table 3.
FAKflox/flox Knockout and FAK Kinase-Dead (KD) Knock-in Mouse Models.
| Type of Cell | Promoter | Phenotype | References |
|---|---|---|---|
| Embryonic vascular ECs | Tie2 | Developmental vasculature defects | (Braren et al. 2006; Shen et al. 2005) |
| Adult vascular ECs | SCL, PDGF-B | Impact on tumor angiogenesis and sensitization tumor cell death by chemotherapy | (Schmidt et al. 2013; Tavora et al. 2010; Tavora et al. 2014; Weis et al. 2008) |
| Keratinocytes | K5, K14 | Inhibition of malignant skin tumor progression | (McLean et al. 2004b; Serrels et al. 2012) |
| Mammary ECs | MMTV | Inhibition of breast tumor formation and metastasis | (Luo et al. 2009b; Nagy et al. 2007) |
| Prostate cells | Probasin | Decreased prostate carcinoma | (Slack-Davis et al. 2009) |
| FAK-KD knockin in ECs (FAKflox/KD) | SCL, Tie2 | Reduced vascular permeability and inhibition of tumor metastasis | (Jean et al. 2014; Zhao et al. 2010) |
SCL, stem cell leukemia; PDGF-B, platelet-derived growth factor-B; K5 and 14, keratin-5 and -14; MMTV, mouse mammary tumor virus.